Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 1437

Sort by

Sort Order Select

Journal Articles

Preclinical Validation of Ubiquitin Receptor PSMD4 As Therapeutic Target in Multiple Myeloma

Yan Song, PhD, Ting DU, PhD, Arghya Ray, PhD, Dharminder Chauhan, PhD, Kenneth C. Anderson, MD

Blood (2019) 134 (Supplement_1): 4403.

https://doi.org/10.1182/blood-2019-122952

Published: 2019

Journal Articles

ILF2 Antisense Oligonucleotide Therapy and a CRISPR/Cas9-Based Screening for DNA Repair Effectors Identify Synthetic Lethal Approaches Enhancing Myeloma Cells Sensitivity to DNA Damage

Natthakan Thongon, PhD, Christopher Jackson, BS, Pamela Lockyer, MS, Jintan Liu, Andrea Santoni, PhD, Ashley Rose, BS, Guillermo Garcia-Manero, MD, Simona Colla, PhD

Blood (2019) 134 (Supplement_1): 685.

https://doi.org/10.1182/blood-2019-129286

Published: 2019

Journal Articles

RIG-I Activation Is Critical for Responsiveness to Checkpoint Blockade

Simon Heidegger, MD, Alexander Wintges, Florian Stritzke, Katja Steiger, Paul-Albert Koenig, Thomas Engleitner, Julius Clemens Fischer, Vladimir Makarov, Christof Winter, Roland Rad, Marcel R.M. van den Brink, MD PhD, Jürgen Ruland, Florian Bassermann, MD PhD, Timothy Chan, Tobias Haas, MD, Hendrik Poeck, MD

Blood (2019) 134 (Supplement_1): 624.

https://doi.org/10.1182/blood-2019-128724

Published: 2019

Journal Articles

Lw-218, a New Flavonoid Compound, Exerts Anti-T-Cell Malignancies Effects Via Autophagy-Mediated Apoptosis

Po Hu, Hui Li, Bao-An Chen, Hua Tang, Zheng Ge, MD PhD, Jing Zhang, Hui Hui, Qing-long Guo

Blood (2019) 134 (Supplement_1): 5756.

https://doi.org/10.1182/blood-2019-122409

Published: 2019

Journal Articles

Low-Dose Triptolide Enhances Bromodomain Inhibitor JQ1-Induced Apoptosis of Acute Myeloid Leukemia Cells Via Down-Regulation of c-Myc Following RAS/MEK/ERK Inhibition

Bing Xu, Yuanfei Shi, Haijun Zhao, Yi Qiu, PhD

Blood (2019) 134 (Supplement_1): 5757.

https://doi.org/10.1182/blood-2019-123740

Published: 2019

Journal Articles

Rituximab and Obinutuzumab Induce Direct B-Cell Death Via B-Cell Receptor (BCR) Signaling, but Rituximab Elicits Stronger BCR-Derived Pro-Survival Signals Diminishing Apoptosis

Jennifer Edelmann, MD PhD, Arran Dokal, MSc, PhD, Karlheinz Holzmann, Dr. rer. nat., David James Britton, BSc, PhD, Emma Vilventhraraja, MSc, PhD, Ryan Jack Smith, PhD, Mark S Cragg, Prof, Andrejs Braun, PhD, Hartmut Döhner, MD, Pedro Cutillas, PhD, John G. Gribben, MD DSc

Blood (2019) 134 (Supplement_1): 1579.

https://doi.org/10.1182/blood-2019-128704

Published: 2019

Journal Articles

Acute Myeloid Leukemia Export Mitochondria in Extracellular Vesicles Which Induces Pro-Tumoral Changes in Bone Marrow Macrophages

Jamie A Moore, BSc, MSc, Jayna J Mistry, BSc, Rebecca H Horton, Charlotte Hellmich, MBBChir, Adam Pattinson, MSc, BSc, Adam Morfakis, BSc, Yu Sun, BSc, MSc, PhD, Matthew Lawes, MD, Christopher J Morris, PhD, Anna Haestier, Kristian M Bowles, MBBS, PhD, Stuart A Rushworth, PhD

Blood (2019) 134 (Supplement_1): 1427.

https://doi.org/10.1182/blood-2019-128447

Published: 2019

Journal Articles

Identification of FASN-Dependent Onco-Metabolic Regulation of the Pentose Phosphate Pathway (PPP) and Nucleotide Metabolism in Non-Hodgkin Lymphoma (NHL)

Ravi Dashnamoorthy, PhD, Afshin Beheshti, PhD, Xiaoyang Su, PhD, Ying Chen, PhD, Maisarah Mokhtar, B.S, Gregory Dolnikowski, Frederick Lansigan, MD, William B Kinlaw, III, MD, Sandeep Dave, MD, Andrew M. Evens, DO, MSc

Blood (2019) 134 (Supplement_1): 1573.

https://doi.org/10.1182/blood-2019-126382

Published: 2019

Journal Articles

Pharmacological Inhibition of MAP2K7 Induces Apoptosis and Cell Cycle Arrest in T-Cell Acute Lymphoblastic Leukemia

Taylor J Chen, BS, Ye Shen, PhD, Cory Seth Bridges, BS, Chun Shik Park, PhD, Jacob J. Junco, PhD, Karen R. Rabin, MD PhD, H. Daniel Lacorazza, PhD

Blood (2019) 134 (Supplement_1): 3889.

https://doi.org/10.1182/blood-2019-129127

Published: 2019

Journal Articles

Ironomycin Induces Diffuse Large B-Cell Lymphoma Cell Death By Targeting Iron Metabolism Addiction

Julie Devin, PharmD, Tatiana Cañeque, Yea-Lih Lin, PhD, Guillaume Cartron, Philippe Pasero, PhD, Caroline Bret, PhD PharmD, Raphael Rodriguez, Jerome Moreaux, PhD

Blood (2019) 134 (Supplement_1): 3960.

https://doi.org/10.1182/blood-2019-129954

Published: 2019

Journal Articles

Aurora Kinase a/MDM2-Mediated SETD2 Loss of Function in Chronic Myeloid Leukemia Patients in Blast Crisis Can be Therapeutically Targeted Inducing Apoptotic Cell Death in a Caspase-Dependent Way

Blood (2019) 134 (Supplement_1): 4142.

https://doi.org/10.1182/blood-2019-126500

Published: 2019

Journal Articles

Pivotal Role of OCL-Derived IGF1 in Drug Resistance and Bone Destruction in MM

Jumpei Teramachi, Kazuaki Miyagawa, DDS, PhD, Delgado-Calle Jesus, PhD, Jolene Windle, PhD, Noriyoshi Kurihara, DDS, PhD, G David Roodman, MD PhD

Blood (2019) 134 (Supplement_1): 4336.

https://doi.org/10.1182/blood-2019-126959

Published: 2019

Journal Articles

Single-Cell RNA-Seq to Assess Differential Responses to Tnfα in Human Hematopoietic Stem and Progenitor Cells in Myeloproliferative Neoplasm

Brianna Craver, MS, Quy Nguyen, Gajalakshmi Ramanathan, PhD, Angela G. Fleischman, MD PhD

Blood (2019) 134 (Supplement_1): 2518.

https://doi.org/10.1182/blood-2019-123480

Published: 2019

Journal Articles

CD3xCD19 Dart Treatment Is Efficient in Venetoclax Resistant CLL and Reverses T Cell Dysfunction

Anne W. J. Martens, MSc, Susanne R. Janssen, MSc, Ingrid A.M. Derks, Sanne Tonino, MD PhD, Eric Eldering, Gerritje J. W. van der Windt, Arnon P. Kater, MD PhD

Blood (2019) 134 (Supplement_1): 3043.

https://doi.org/10.1182/blood-2019-123350

Published: 2019

Journal Articles

Proteomic Analysis Identifies Mechanism(s) of Overcoming Bortezomib-Resistance Via Targeting Ubiquitin Receptor Rpn13

Ting Du, PhD, Yan Song, PhD, Arghya Ray, PhD, Dharminder Chauhan, PhD, Kenneth C. Anderson, MD

Blood (2019) 134 (Supplement_1): 3074.

https://doi.org/10.1182/blood-2019-130236

Published: 2019

Journal Articles

In Vitro and in Vivo Activity of Melflufen in Amyloidosis

Ken Flanagan, PhD, Muntasir M Majumder, MSc, BPharm, Romika Kumari, PhD, Juho Miettinen, PhD, Ana Slipicevic, PhD, Sarah A. Holstein, MD PhD, Michelle L. Varney, MS, Minna Suvela, MSC, Fredrik Lehmann, PhD, Nina N. Nupponen, PhD, Caroline A Heckman, PhD

Blood (2019) 134 (Supplement_1): 3100.

https://doi.org/10.1182/blood-2019-125952

Published: 2019

Journal Articles

Specific Targeting of KRAS Using a Novel High-Affinity KRAS Antisense Oligonucleotide in Multiple Myeloma

Blood (2019) 134 (Supplement_1): 3104.

https://doi.org/10.1182/blood-2019-124391

Published: 2019

Journal Articles

Initial Characterization and Toxicology of an Nmt Inhibitor in Development for Hematologic Malignancies

Michael Weickert, John Dillberger, John R. Mackey, Paul Wyatt, David Gray, Kevin Read, Christian Li, Audrey Parenteau, Luc G. Berthiaume

Blood (2019) 134 (Supplement_1): 3362.

https://doi.org/10.1182/blood-2019-124934

Published: 2019

Journal Articles

The Preclinical Activities of PTC596, a Novel Tubulin Binding Agent That Down-Regulates BMI1, Alone and in Combination with Bortezomib in Multiple Myeloma

Blood (2019) 134 (Supplement_1): 4414.

https://doi.org/10.1182/blood-2019-122350

Published: 2019

Journal Articles

Targeting the p62-ZZ/N-End Rule Pathway in Multiple Myeloma Overcomes Proteasome Inhibitor-Resistance Via Induction of Necroptosis and Enhances the Bone Anabolic Effects of Proteasome Inhibitors

Silvia Marino, PhD, Daniela Nicoleta Petrusca, PhD, Edward Simpson, PhD, Judith L Anderson, BS, Xiang-Qun Xie, PhDMD,MBA, Yunlong Liu, PhD, John Chirgwin, PhD, G. David Roodman, MD PhD

Blood (2019) 134 (Supplement_1): 4391.

https://doi.org/10.1182/blood-2019-131865

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Preclinical Validation of Ubiquitin Receptor PSMD4 As Therapeutic Target in Multiple Myeloma

ILF2 Antisense Oligonucleotide Therapy and a CRISPR/Cas9-Based Screening for DNA Repair Effectors Identify Synthetic Lethal Approaches Enhancing Myeloma Cells Sensitivity to DNA Damage

RIG-I Activation Is Critical for Responsiveness to Checkpoint Blockade

Lw-218, a New Flavonoid Compound, Exerts Anti-T-Cell Malignancies Effects Via Autophagy-Mediated Apoptosis

Low-Dose Triptolide Enhances Bromodomain Inhibitor JQ1-Induced Apoptosis of Acute Myeloid Leukemia Cells Via Down-Regulation of c-Myc Following RAS/MEK/ERK Inhibition

Rituximab and Obinutuzumab Induce Direct B-Cell Death Via B-Cell Receptor (BCR) Signaling, but Rituximab Elicits Stronger BCR-Derived Pro-Survival Signals Diminishing Apoptosis

Acute Myeloid Leukemia Export Mitochondria in Extracellular Vesicles Which Induces Pro-Tumoral Changes in Bone Marrow Macrophages

Identification of FASN-Dependent Onco-Metabolic Regulation of the Pentose Phosphate Pathway (PPP) and Nucleotide Metabolism in Non-Hodgkin Lymphoma (NHL)

Pharmacological Inhibition of MAP2K7 Induces Apoptosis and Cell Cycle Arrest in T-Cell Acute Lymphoblastic Leukemia

Ironomycin Induces Diffuse Large B-Cell Lymphoma Cell Death By Targeting Iron Metabolism Addiction

Aurora Kinase a/MDM2-Mediated SETD2 Loss of Function in Chronic Myeloid Leukemia Patients in Blast Crisis Can be Therapeutically Targeted Inducing Apoptotic Cell Death in a Caspase-Dependent Way

Pivotal Role of OCL-Derived IGF1 in Drug Resistance and Bone Destruction in MM

Single-Cell RNA-Seq to Assess Differential Responses to Tnfα in Human Hematopoietic Stem and Progenitor Cells in Myeloproliferative Neoplasm

CD3xCD19 Dart Treatment Is Efficient in Venetoclax Resistant CLL and Reverses T Cell Dysfunction

Proteomic Analysis Identifies Mechanism(s) of Overcoming Bortezomib-Resistance Via Targeting Ubiquitin Receptor Rpn13

In Vitro and in Vivo Activity of Melflufen in Amyloidosis

Specific Targeting of KRAS Using a Novel High-Affinity KRAS Antisense Oligonucleotide in Multiple Myeloma

Initial Characterization and Toxicology of an Nmt Inhibitor in Development for Hematologic Malignancies

The Preclinical Activities of PTC596, a Novel Tubulin Binding Agent That Down-Regulates BMI1, Alone and in Combination with Bortezomib in Multiple Myeloma

Targeting the p62-ZZ/N-End Rule Pathway in Multiple Myeloma Overcomes Proteasome Inhibitor-Resistance Via Induction of Necroptosis and Enhances the Bone Anabolic Effects of Proteasome Inhibitors

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only